Iopofosine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 578240

CAS#: 208986-26-9

Description: Iopofosine, also known as NM-404, is a phospholipid drug conjugate which targets delivery of iodine 131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells. Iopofosine I-131 demonstrated tumoricidal capacity in preclinical HNC tumor models and the theranostic pairing with CLR 124 presents a promising new treatment approach for personalizing administration of iopofosine I-131. Note: Iopofosine that we listed here is not a radioiodinated compound.

Chemical Structure

img
Iopofosine
CAS# 208986-26-9
Instruction

Theoretical Analysis

MedKoo Cat#: 578240
Name: Iopofosine
CAS#: 208986-26-9
Chemical Formula: C29H53INO4P
Exact Mass: 637.28
Molecular Weight: 637.620
Elemental Analysis: C, 54.63; H, 8.38; I, 19.90; N, 2.20; O, 10.04; P, 4.86

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CLR-1401; CLR 1401; CLR1401; NM-404; NM 404; NM404; Iopofosine;

IUPAC/Chemical Name: Ethanaminium, 2-((hydroxy((18-(4-iodophenyl)octadecyl)oxy)phosphinyl)oxy)-N,N,N-trimethyl-, inner salt

InChi Key: ZOAIEFWMQLYMTF-UHFFFAOYSA-N

InChi Code: InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3

SMILES Code: C[N+](C)(C)CCOP(=O)([O-])OCCCCCCCCCCCCCCCCCCc1ccc(I)cc1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 637.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Marsh IR, Li C, Grudzinski J, Jeffery J, Longhurst C, Adam DP, Hernandez R, Weichert JP, Harari PM, Bednarz BP. Targeting of Head and Neck Cancer by Radioiodinated CLR1404 in Murine Xenograft Tumor Models with Partial Volume Corrected Theranostic Dosimetry. Cancer Biother Radiopharm. 2023 Sep;38(7):458-467. doi: 10.1089/cbr.2022.0084. Epub 2023 Apr 5. PMID: 37022739; PMCID: PMC10516227.


2: Schroeder HW, Hall LT. Molecular Imaging of Brain Metastases with PET. In: Sergi CM, editor. Metastasis [Internet]. Brisbane (AU): Exon Publications; 2022 May 3. Chapter 1. PMID: 35679455.


3: Neira S, Gago-Arias A, Gónzalez-Crespo I, Guiu-Souto J, Pardo-Montero J. Development of a Compartmental Pharmacokinetic Model for Molecular Radiotherapy with 131I-CLR1404. Pharmaceutics. 2021 Sep 17;13(9):1497. doi: 10.3390/pharmaceutics13091497. PMID: 34575575; PMCID: PMC8465706.


4: Neira S, Gago-Arias A, Guiu-Souto J, Pardo-Montero J. A kinetic model of continuous radiation damage to populations of cells: comparison to the LQ model and application to molecular radiotherapy. Phys Med Biol. 2020 Dec 10;65(24):245015. doi: 10.1088/1361-6560/aba21d. PMID: 32615551.


5: Hall LT, Titz B, Baidya N, van der Kolk AG, Robins HI, Otto M, Perlman SB, Weichert JP, Kuo JS. [124I]CLR1404 PET/CT in High-Grade Primary and Metastatic Brain Tumors. Mol Imaging Biol. 2020 Apr;22(2):434-443. doi: 10.1007/s11307-019-01362-1. PMID: 31183841; PMCID: PMC7485611.


6: Marsh IR, Grudzinski J, Baiu DC, Besemer A, Hernandez R, Jeffery JJ, Weichert JP, Otto M, Bednarz BP. Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models. J Nucl Med. 2019 Oct;60(10):1414-1420. doi: 10.2967/jnumed.118.225409. Epub 2019 Mar 29. PMID: 30926646; PMCID: PMC6785791.


7: Besemer AE, Grudzinski JJ, Weichert JP, Hall LT, Bednarz BP. Pretreatment CLR 124 Positron Emission Tomography Accurately Predicts CLR 131 Three-Dimensional Dosimetry in a Triple-Negative Breast Cancer Patient. Cancer Biother Radiopharm. 2019 Feb;34(1):13-23. doi: 10.1089/cbr.2018.2568. Epub 2018 Oct 23. PMID: 30351218; PMCID: PMC6383576.


8: Grudzinski J, Marsh I, Titz B, Jeffery J, Longino M, Kozak K, Lange K, Larrabee J, Weichmann A, Moser A, Bednarz B. CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast Cancer. Cancer Biother Radiopharm. 2018 Apr;33(3):87-95. doi: 10.1089/cbr.2017.2376. PMID: 29641256; PMCID: PMC5905872.


9: Hall LT, Titz B, Robins HI, Bednarz BP, Perlman SB, Weichert JP, Kuo JS. PET/CT imaging of the diapeutic alkylphosphocholine analog 124I-CLR1404 in high and low-grade brain tumors. Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):157-166. PMID: 28913154; PMCID: PMC5596318.


10: Baiu DC, Marsh IR, Boruch AE, Shahi A, Bhattacharya S, Jeffery JJ, Zhao Q, Hall LT, Weichert JP, Bednarz BP, Otto M. Targeted Molecular Radiotherapy of Pediatric Solid Tumors Using a Radioiodinated Alkyl-Phospholipid Ether Analog. J Nucl Med. 2018 Feb;59(2):244-250. doi: 10.2967/jnumed.117.193748. Epub 2017 Jul 26. PMID: 28747518; PMCID: PMC5807534.


11: Besemer AE, Titz B, Grudzinski JJ, Weichert JP, Kuo JS, Robins HI, Hall LT, Bednarz BP. Impact of PET and MRI threshold-based tumor volume segmentation on patient-specific targeted radionuclide therapy dosimetry using CLR1404. Phys Med Biol. 2017 Jul 6;62(15):6008-6025. doi: 10.1088/1361-6560/aa716d. PMID: 28682793; PMCID: PMC6771923.


12: Clark PA, Al-Ahmad AJ, Qian T, Zhang RR, Wilson HK, Weichert JP, Palecek SP, Kuo JS, Shusta EV. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood- Brain Barrier Model. Mol Pharm. 2016 Sep 6;13(9):3341-9. doi: 10.1021/acs.molpharmaceut.6b00441. Epub 2016 Aug 4. PMID: 27421304; PMCID: PMC5014630.


13: Marino R, Baiu DC, Bhattacharya S, Titz B, Hebron E, Menapace BD, Singhal S, Eickhoff JC, Asimakopoulos F, Weichert JP, Otto M. Tumor-selective anti-cancer effects of the synthetic alkyl phosphocholine analog CLR1404 in neuroblastoma. Am J Cancer Res. 2015 Oct 15;5(11):3422-35. PMID: 26807322; PMCID: PMC4697688.


14: Lubner SJ, Mullvain J, Perlman S, Pishvaian M, Mortimer J, Oliver K, Heideman J, Hall L, Weichert J, Liu G. A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies. Cancer Invest. 2015;33(10):483-9. doi: 10.3109/07357907.2015.1081691. Epub 2015 Nov 4. PMID: 26536061.


15: Morris ZS, Weichert JP, Saker J, Armstrong EA, Besemer A, Bednarz B, Kimple RJ, Harari PM. Therapeutic combination of radiolabeled CLR1404 with external beam radiation in head and neck cancer model systems. Radiother Oncol. 2015 Sep;116(3):504-9. doi: 10.1016/j.radonc.2015.06.015. Epub 2015 Jun 26. PMID: 26123834; PMCID: PMC4609259.


16: Grudzinski JJ, Titz B, Kozak K, Clarke W, Allen E, Trembath L, Stabin M, Marshall J, Cho SY, Wong TZ, Mortimer J, Weichert JP. A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. PLoS One. 2014 Nov 17;9(11):e111652. doi: 10.1371/journal.pone.0111652. PMID: 25402488; PMCID: PMC4234270.


17: Deming DA, Maher ME, Leystra AA, Grudzinski JP, Clipson L, Albrecht DM, Washington MK, Matkowskyj KA, Hall LT, Lubner SJ, Weichert JP, Halberg RB. Phospholipid ether analogs for the detection of colorectal tumors. PLoS One. 2014 Oct 6;9(10):e109668. doi: 10.1371/journal.pone.0109668. PMID: 25286226; PMCID: PMC4186834.


18: Weichert JP, Clark PA, Kandela IK, Vaccaro AM, Clarke W, Longino MA, Pinchuk AN, Farhoud M, Swanson KI, Floberg JM, Grudzinski J, Titz B, Traynor AM, Chen HE, Hall LT, Pazoles CJ, Pickhardt PJ, Kuo JS. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci Transl Med. 2014 Jun 11;6(240):240ra75. doi: 10.1126/scitranslmed.3007646. PMID: 24920661; PMCID: PMC4336181.


19: Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrooks M, Clipson L, Albrecht D, Bacher J, Washington MK, Weichert J, Halberg RB. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene. 2014 Apr 24;33(17):2245-54. doi: 10.1038/onc.2013.167. Epub 2013 May 27. PMID: 23708654; PMCID: PMC3883937.


20: Leystra AA, Deming DA, Zahm CD, Farhoud M, Olson TJ, Hadac JN, Nettekoven LA, Albrecht DM, Clipson L, Sullivan R, Washington MK, Torrealba JR, Weichert JP, Halberg RB. Mice expressing activated PI3K rapidly develop advanced colon cancer. Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23. PMID: 22525701; PMCID: PMC3645915.